USA: Ceribell Secures FDA Clearance for Clarity™ AI Algorithm in Pediatric Seizure Detection

CeriBell, Inc., a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older. This makes Ceribell the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures in children as young as 1 year old and to fully cover the age range from 1 year old to adult. Using Ceribell’s comprehensive solution, clinicians will be empowered to detect non-convulsive seizures in pediatric patients in real time, supporting rapid diagnosis and treatment to help prevent serious brain injury in one of the most common neurological emergencies that children face.

Based on Ceribell’s assessment, its Clarity algorithm now provides coverage across the largest age range ever addressed by a seizure detection technology. This offers hospitals, particularly emergency departments and ICUs, a complete solution for detecting electrographic seizures in both pediatric and adult patients. The pediatric clearance was supported by electroencephalography (EEG) data collected from over 1,700 patients, which FDA data indicates is the largest validation dataset ever used for FDA clearance of a seizure detection system, reflecting the scale of Ceribell’s extensive EEG database and the rigor of its validation process and algorithm. The Clarity algorithm is designed to be used with the same Ceribell EEG headbands currently marketed for adults, which are cleared for use in patients of all ages.

"We believe this clearance will have a profound impact on the lives of critically ill children, who are particularly vulnerable to preventable brain injury," said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "It is well understood that seizures can lead to poor clinical outcomes when not treated in a timely manner. Yet, until now, clinicians have never had access to point-of-care EEG with a seizure detection algorithm tailored specifically for pediatric patients as young as 1 year old. This breakthrough, which we expect to be commercially available soon, marks another important step toward our mission of making rapid EEG the standard of care for everyone."

Seizures are a leading cause of neurology-related pediatric emergency department visits.² Non-convulsive seizure activity, which can only be detected with EEG, must be quickly identified and treated to prevent brain injury. Clinical guidelines recommend initiating EEG within 15–60 minutes of suspected continuous non-convulsive seizures in both children and adults. In practice, however, children often wait hours or even days for EEG assessment. Ceribell’s easy-to-use, AI-powered point-of-care EEG helps fill this critical gap by enabling prompt bedside neurological assessment and providing real-time insights into a patient’s condition.